Drug Profile

TRC 093

Alternative Names: D-93; MT-293; TRC-093

Latest Information Update: 24 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Micromet Inc
Developer TRACON Pharmaceuticals
Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
Mechanism of Action Angiogenesis inhibitors; Collagen modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Age-related macular degeneration; Solid tumours

Most Recent Events

12 Nov 2024 Discontinued - Phase-I for Solid tumours in USA (IV) (TRACON Pharmaceuticals website, November 2024)
12 Nov 2024 Discontinued - Preclinical for Age-related macular degeneration in USA (IV) (TRACON Pharmaceuticals website, November 2024)
16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com